This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk09: Thank you for continuing to hold. We will begin the conference momentarily.
spk00: IGHTER MED館 失职 armies Z.
spk09: Good day and welcome to the Green Thumb Industries Second Quarter 2024 earnings conference call and webcast. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. On today's call, management will provide prepared remarks and then we will open up the call for your questions. To ask questions, analysts may press star then one on their touchstone phones. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Shannon Weaver. Please go ahead ma'am.
spk07: Thanks Nick. Good afternoon and welcome to Green Thumb Second Quarter 2024 earnings call. I'm here today with founder and CEO Ben Koehler, President Anthony Torgattas, and Chief Financial Officer Matt Faulkner. Today's discussion and responses to questions may include forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. These risks and uncertainties are detailed in the earnings press release issued today, along with the reports filed with the United States Securities and Exchange Commission and Canadian securities regulators, including our most recent annual report filed on Forum 10K. This report, along with today's earnings release, can be found under the Investors section of our website. Green Thumb assumes no obligation to update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this call. Throughout the discussion, Green Thumb will refer to non-GAAP financial measures, including EBITDA and adjusted EBITDA. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in our earnings press release and SEC and CEDA filings. Please note all financial information is provided in U.S. dollars unless otherwise indicated. Thanks everyone, and now your turn.
spk02: Thank you Shannon. Good afternoon everyone, and thank you for joining our second quarter 2024 conference call. I'm pleased to report that our team delivered another strong quarter with revenue of 11% over the prior year to $280 million and over $90 million in EBITDA. Importantly, cash flow from operations was $20 million after paying almost $53 million in two tax installments this quarter. On June 28, the IRS issued a statement that made it clear that cannabis companies were obligated to pay taxes under 280E while cannabis remains a Schedule 1 controlled substance. Thus, the regulatory attention is squarely on the DEA and leader Anne Milgram and whether or not she chooses to reschedule cannabis to Schedule 3, engage in an AOJ review process, or stay silent until the next administration. For the good of the country, we encourage Anne Milgram to do her job and reschedule cannabis immediately. No more waiting. During the second quarter, we also repurchased 1.6 million shares for approximately $20 million, bringing the aggregate spend under the share repurchase program to $73 million for approximately 6.6 million shares. Under the current program, we still have the option to repurchase almost $27 million in shares. We believe in the value creating nature of share buybacks at attractive prices. We ended the quarter with $196 million in cash. That's plenty of dry powder to execute our capital allocation plan for 2024 and beyond. From an industry perspective, there is still price compression in most markets as well as inflationary pressure. Not to mention national anxiety around the upcoming elections. Despite this uncertainty, we are focused on the product, our brand, and the relationship with the consumer. Green Thumb will continue following our same playbook since day one, scaling our business to retail store expansion, building out our wholesale business, leveraging operational efficiencies, and carefully managing our balance sheet. Green Thumb has some of the top rated brands in the business. Rhythm, Dog Walkers, Incredibles, and Bevo. And we're focusing a lot of energy this year on expanding brand awareness by creating meaningful experiences for consumers, authentic relationships, especially through the power of music. We recently announced that our Miracle Among the Lines two-day festival will be back this year with a highly anticipated lineup of musicians, including cannabis icon Wiz Khalifa. The Rhythm Artist Series features strains chosen and smoked by artists such as multi-platinum R&B disruptor Tinashe. Tinashe's Green Key has created a lot of great buzz. Music is also at the core of Blood Ball, an annual concert we throw in-market, which we opened up to Philly for the first time this year. We saw record turnout at these events, and the Find Your Rhythm lifestyle was on full display.
spk00: We are
spk02: also excited to bring more of our brands to new markets, with Bevo launching in New York just last month, and that's going well, and plans to expand to New Jersey very soon. We like the progress in our brands, but believe this is just the beginning of how these lifestyle brands will live in America. We want our brands to become integral to the American experience, and we are intensely watching consumer trends. We believe alcohol is melting, and for folks under 35 years old, alcohol is a lot less appealing than it was for their parents. This line of thinking led us to approach Boston Beer about a possible combination. Green Thumb has 50% more Giba Dots in Boston Beer, and we think consumer trends will force Boston Beer and others to diversify away from alcohol into products the future American consumer wants. I outlined the benefits of combining our two businesses, including a potential U.S. listing for Green Thumb, in my letter to Boston Beer's chairman and founder, and posted that on X. It often takes time for an incumbent industry to recognize and embrace change. In the meantime, Green Thumb will do what we have always done, keep our head down and execute, focus on building shareholder value through prudent capital allocations, all the while using the consumer as our North Star. Stopping for a moment and looking around to where we are, we feel good. Green Thumb is gaining market share in U.S. cannabis as our brands build momentum. Furthermore, we are well positioned in the emerging cannabis markets like Ohio, where we will kick off adult use sales at all five of our rise dispensaries tomorrow morning. Looking forward to seeing our incredible team in action on day one in the Buckeye State. We see a nice, long runway for growth and are confident in our team's abilities to strategically and profitably scale our business in Ohio. With that, I'll turn the call over to Anthony. Anthony?
spk03: Thanks, Ben. As you just heard, despite continued consumer inflationary headwinds, our team achieved record second quarter results. Let's take a look at some of the highlights. First, we invested approximately $20 million in capbacks as we continue to expand our Florida retail footprint as well as our Connecticut wholesale facility. Through June, we've opened three new stores and anticipate opening another seven to eight stores in the back half of the year. Year to date, we've invested approximately $35 million in capbacks and expect to invest an additional $50 to $60 million in capbacks throughout the remainder of the year. Second, we continue to drive strong CPG performance across our fleet and increased our CPG revenue by over 15% compared to Q2 of last year. As our retail business continues to absorb the impact of price erosion and greater competition, we plan to enhance our market positions by increasing both the depth and breadth of our product lines and their placement on third-party shelves. For those that saw it, Bebo recently launched in New York, and we are incredibly excited to introduce her to the Big Apple. Third, we prepared for tomorrow's Ohio launch. We have the team hired, the stores ready, and our menus are stacked with something for everyone. Our recent adult use conversions in New Jersey, New York, and Maryland have prepared us well for tomorrow's historic event. As we look ahead to the balance of the year, our team is focused on the following. First, optimizing our business. This means different things depending on market dynamics and our position within each market. However, when you zoom out, it comes down to focusing on the consumer, our team, and execution. Second, driving continued distribution of our CPG brand through our rising retail stores as well as third-party stores. While we've made substantial progress on this front, we have more work to do to continue to expand the reach of our industry-leading brands, including Rhythm and Dogwalkers. Third, continuing to invest our resources and capital in markets where we can underwrite strong returns. The balance of our 2024 Apex plan helps continue retail and wholesale investments in Florida, Nevada, Minnesota, Pennsylvania, and Virginia. Last, preparing for our momentous second miracle of Mundelein on September 7th and 8th at our flagship Illinois store, Mundelein. For those unfamiliar, this two-day festival for attendees 20-minute over allows for legal cannabis consumption. This year's event showcases Ways to Reboot, Slightly Stupid, and Revolution. We hope to see you there. In conclusion, we are excited to announce that the annual Mundelein event is now over. In conclusion, we did want to call out HEM because we've received a lot of questions on this topic. As previously disclosed, we entered the HEM market via a license agreement with our Incredibles brand. Through that relationship, we are studying the consumer, the players, the product, the risks, and other facets of the market, including overall potential. Since we are in the early days of our exploration, it would be premature for us to comment more than that. However, our North Star always has been and always will be the consumer. With that, we'll turn the call over to Matt to review our financial results. Matt?
spk11: Thanks, Anthony, and hello everyone. We're pleased with the strong results and record cash flow generation. In the second quarter, we delivered over $280 million in revenue, an 11% increase compared to the prior year period. Revenue during the quarter benefited from 11 incremental retail stores and the legalization of adult use sales in Maryland. While pricing year over year continued to the downward slide, the sequential impact took a turn for the worse in Q2 compared to Q1's improvement. Overall, retail revenue increased 9% versus the prior year period. The second quarter comparable sales increased .3% compared to the second quarter last year on a base of 76 stores. Consumer package goods gross revenue increased 15% versus the prior year quarter. Looking forward, we expect to see third quarter sequential revenue to be flat as we watch macro consumer spending pullback with some expected benefits from Ohio adult use launch. Growth profit for the second quarter was 151 million, or .7% of revenue, compared to 125 million, or .6% of revenue for the second quarter last year. The increase in gross margin was primarily driven by improved CPG utilization and retail acquisition costs. Turning to OPEX, selling general administrative expenses for the second quarter, or 97 million, or 34% of revenue, compared to 84 million, or 33% of revenue last year, was a compensation cost driving the increase. SG&N excluded depreciation, amortization, one-time transaction, VOS, and stock-based comp, which we refer to as normalized operating costs, approximated 67 million compared to 57 million in the second quarter last year. The increase year over year is mainly attributed to the 11 incremental retail stores. The second quarter net income was 21 million, or 9 cents per basic and diluted share during the quarter. This compares to net income 13 million, or 5 cents per basic and diluted share reported last year. The adjusted EBITDA, which excludes non-cash stock-based compensation and other non-operated costs, was 94 million, or .5% of revenue for the quarter, as compared to 76 million, or 30% of revenue for the second quarter last year, with the increase driven by margin improvement. The end of the second quarter was a strong balance sheet including cash of 196 million and cash flow from operations of 104 million compared to 93 million last year, all while paying 53 million in income taxes so far this year. In closing, I'm very proud of our team for all their hard work and execution in the second quarter. I'm confident in our ability to continue to execute our strategic plan to deliver high-quality cannabis to our patients and customers, all while generating strong returns for our shareholders. With that, we'll open the call to your questions. Operators?
spk09: Thank you. We will now begin the question and answer session. To ask a question, you may press star, then 1 on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then 2. In the interest of time, we ask that you please limit yourself to one question only. At this time, we will pause momentarily to assemble our roster. The first question comes from Matt Bottomley with Cannacor Genuity. Please go ahead.
spk13: Good evening, everyone. Thanks for the question. Ben, just wondering if I can get a little more color from you with respect to your anticipation in Ohio, not in terms of specific monetary guidance or anything like that, but if you relate it to maybe what we saw in Maryland where that was almost effectively a doubling of the market within months, given that you're already at the state level max of five, I'm just wondering if you can give us an idea of what the back half of the year might suggest considering that market's turning online tomorrow.
spk02: Yeah, hey, Matt. Thanks, Ben. Yeah, you're right. I mean, just a level set for everybody. On Friday, we learned that Ohio would start adult mutes tomorrow, so Tuesday of this week, which is tomorrow. For RISE, that means all five stores will convert to 21 and over. Folks can come in and buy for the first time. And this is not new for us, right? Like you said, Matt, we led the charge in New Jersey, we led the charge in Maryland, we led the charge in Illinois, we've been around for Nevada, Massachusetts, New York, Pennsylvania, and New York. We've been around for a while now, and we've been to New York and several others. So we're optimistic. I'm not sure what else to tell you except numbers. So the numbers I would tell you are, yeah, we think it's easily a double as a market. Holistically, it should be bigger. Ohio's been hampered for several different reasons, product, branding, sizing. We're optimistic about the new regulator in the future, and we're excited about tomorrow. So, you know, we don't see a gangbusters boulder at a pond start. We see Crawl Walk run, making sure this thing gets off to a good start. Everybody's on the same page, and we're excited for tomorrow. I'll be out there. Everybody's welcome. 21 over, bring your ID, and we'll see you at RISE throughout Ohio.
spk13: And sorry, any capacity constraints in that market, just to slip another quote in there?
spk03: Yeah, Matt, I can take that question. So, you know, we are fully built out. So for everyone's benefit, the store or the state has at least before adult use started had a statutory limit of five stores per operator, and then had a canopy cap. So we were at the max on both of those limits. Now with adult use, the canopy cap increases as well as the store count. It goes from five to eight. At the moment, we're fully locked and loaded, and then obviously when the adult use rates go into effect in early September, that's when we'll take a closer look at the canopy expansion, along with we already have a path to open up the additional stores
spk04: from five to eight. Thanks, all.
spk09: Again, in the interest of time, we ask that you please limit yourself to one question. The next question comes from Eric DeLaurier with Craig Hallam Capital Group. Please go ahead.
spk05: Great. Thanks for taking my questions, and congrats on another impressive quarter here. So your ability to continue gaining market share and realizing operating efficiencies continues to be impressive. So you talk about where you see opportunities to continue that momentum and how that plays into your capex plans for the second half, and then just kind of higher level. Should we be thinking about your efficiency gains and ability to kind of offset price compression as more a function of capex projects or operating cost leverage? Thank you.
spk02: Yeah, I can start, Eric, and maybe Anthony will come in on the second part. So I think the first part is where's the growth? Where are we optimistic going forward? I think, you know, we think you have an edge on the vision of what's happening in cannabis in the country. So it's sort of like to have the pieces in place ahead of time, which means tomorrow morning open five stores for non-medical sales in Ohio. And what that means in the next year or two are places like Virginia, Minnesota, and a few other states on the market. And then it's even thinking outside the box and being ahead of that. So, you know, we have the balance sheet to do it and we have the ability and the power to, you know, to make a few mistakes too and not tip over the boat. So we see our ability to play offense and really accelerate on the gas and press and press big time. You know, that's what we're doing for the advantage of shareholders. So it's a pretty good situation where we are there in terms of the actual details, the operating efficiencies and price.
spk03: Yeah, yeah. Look, I think just we look ahead, you know, I think we're showing it in terms of kind of where we're allocating capital, right? And the fact that we continue to allocate capital. We've been one of the bigger kind of, you know, investors into our business than any other operator. And as we look ahead, you know, we've had to continue to sharpen the pencil and just make sure that the returns continue to pencil out to the shareholders. And so, you know, now I think in my prepared remarks I mentioned that where we're allocating the dollars really is Florida, Nevada, Minnesota, and South Carolina. And so that's the case in Minnesota, Pennsylvania, and Virginia. How that evolves over time we'll see. But we see opportunities within those markets to deploy capital as returns that make sense for shareholders. You know, and then in terms of our performance and ability to continue to kind of, you know, drive strong operating performance, it's on the heels of the capital spend. So, you know, as we enter in these markets, we stand up at facilities. We continue to optimize kind of our presence within those facilities and we grow into them. And that's how we've been able to continue to, you know, effectively show strong kind of, you know, marketing performance. On top of that, you know, it's all supported by the strength of our brand and the quality of our products. And that's going to continue to be kind of, you know, two pillars that we're going to have to continue to lean on as these markets, you know, just continue to become more competitive and more challenging.
spk05: So, very helpful. Thank you for taking my question.
spk09: The next question comes from Pablo Zouanek with Zouanek and Associates. Please go ahead.
spk01: Thank you. Ben, can you maybe give more context regarding your letter to Jim Cook regarding the merger with Boston Beer? I mean, obviously I know it's something that you guys thought through very carefully and it's not a publicity stunt for sure. But, you know, they are low growth, right? Why dilute your story with a low growth company? The idea of a U.S. listing, I mean, there's no, Boston Beer could lose their Nasdaq listing if they were to merge with a plant touching company, right? At least that's what we've seen from other cases, even the ones that are trying to have ring fence structure. So maybe just some context about what you tried to do there. And then number two, if I can, I know you said not a lot of comments on hemp. From my perspective, there are good players out there in hemp that are, you know, following the rules and their products are tested and they go through a lapse in the various states. And that's why probably you chose LFTD Partners as a partner there. But maybe give a bit more context if you can because I find that when I read out there, it sounds like everything that's in the UATB is bad. And obviously there are products that are properly produced and tested. Thank you. Thanks, Pablo.
spk02: I mean, I honestly don't have much more to say than the letter. I think we've been pretty forthcoming in what our thinking is. So I'm not going to re-articulate it here. I think just for the record, there are listed companies on U.S. exchanges that don't like this to operate marijuana in regulated markets. They're taking in revenue and they're listed. So we, you know, we think of U.S. listing as just a matter of time, the right lawyers, the right conversations, and the right sort of blow of the wind for people to feel the right color. But again, for U.S. American citizens to not be able to buy stock in the American company that rolls the joints that they smoke doesn't make any sense. So eventually we know that that's going to be a fact. And you don't buy what you own. Peter Lynch style investing should take over for this sector because American consumers, especially young, new, interested consumers, want to have access to this sector. And so far it's been blocked out. Doesn't make sense. Again, there's 428,000 Americans that work in cannabis and they're all breaking federal law right now. And, you know, everybody in D.C. seems distracted and not quite able to get around to it. So it's quite frustrating. But we agree that there's a listing on the U.S. exchange here eventually. I can't tell you when, but obviously we can follow and put this to the other big companies that are listed on the New York Stock Exchange or NASDAQ that are in the marijuana business. Yeah, I think,
spk03: Paul, a good call out and good comments on hemp. You know, again, I think my prepared remarks kind of set it best. We're at the very early stages of our exploration here. You know, one of the things I said, we're studying the players. So absolutely, there are some operators that we've come across that seem to be doing a nice job. Unfortunately, not everyone seems to be kind of falling within those same guidelines. But we're at the early stages and my guess is over time, you know, we'll start to kind of really peel back the onion here and understand how and if we play in this market. You know, we also said that the consumer is really what our main focus is on. So that at the end of the day, we're going to be focused on that. And so, you know, we have to keep our eyes wide open as this game continues to
spk04: evolve. Thank you.
spk09: The next question comes from Aaron Gray with Alliance Global Partners. Please go ahead.
spk12: Hi, good evening and thank you for the question. Nice question. Nice execution on the CPG side of the business. You know, both year over year, but also on a mid-single digit basis, taking away the Maryland adult use impact. So could you provide some color in terms of, you know, standouts in terms of formats or brands or you have seen the most success in the first half of the year for that? And then, you know, you spoke about pricing pressure in this sector. Can you speak to your current comfortability in terms of the price gaps within respective price segments and whether or not that's changed and driven some success that you've seen? Thank you.
spk00: Alright,
spk03: Aaron, there's a lot of you are coming through a little, a little mumbled there, but your first question related to specific to Maryland in terms of the products and the brands that are having a lot of traction in the market. Is that it? Did you catch that right?
spk12: No, first question was just overall CPG success and what formats or brands have been standouts.
spk03: Okay, so yeah, let's answer that first. So in terms of the products and the brands we look, it's, you know, Rhythm and Dog Walkers, along with Strength, Rhythm and Incredibles and Vivo, depending on the market and where they're launched. But overall, we're pretty pleased. You know, we look at the same data as everyone else. We take a look at VDS and -to-head data and, you know, in many markets, we're making strong progress. There's some markets where maybe we're not making the progress that we'd like to be making and I can tell you we're going to be working hard on those. But taking a step back, we feel really good about the progress we've made thus far. And again, it comes back to high quality products, right? We've got Strength within the flower category, given how we kind of built this business with, you know, highly automated indoor facilities that can achieve, you know, just exceptional kind of, you know, humidity and temperature levels and whatnot. We have the ability to produce the high quality flower. That helps us on the rhythm side as well as the Dog Walker side of the business. And then it's really continuing to meet the consumer with where the demand is, you know, within a category 6 pre-roll that, you know, that has nice growth associated with it. So that's really where we've been focused and so far we've had some nice success, as you showed us in the numbers, within the first half of the year.
spk12: Okay, great. Thanks, Matt. Yeah, the second part of that was just your comfortability in terms of price gaps within all respective price segments for your brands.
spk03: Look, here the data is much more murky and the real challenging factor is life for life skews. Particularly right now, what we're seeing, you know, with the consumer, you know, just on the retail side, you know, the store visits are there, the traffic is there. But there's an essential kind of just trading down in bulk purchasing that's happening that effectively is driving down, you know, the overall, you know, revenue program. That's a metric that you track, which for us is. So it's hard to really look at apples to apples compared again kind of, you know, other brands, other categories, life for life. It's just incredibly challenging. So for us, you know, the way that we're looking at it is, you know, we look at how the price of our own products within our own retail stores relative to third party products. And if we can get a sense for value, if we feel good about the value that effectively our products are carrying on the shelf, that's really the first step. And that's what gives us the confidence that we're pricing our product correctly.
spk13: Great. Thanks for that. I'll jump back in the queue.
spk09: The next question comes from Frederick Smith with ATB Capital. Please go ahead.
spk10: Hi, thanks for taking my question. Congrats on the quarter. Just on New York, could you comment on what you're seeing there in the adult use market, especially, you know, with the crackdown that we're seeing on the listed store side? Are you seeing any meaningful benefits from that enforcement against the listed market and do you think that New York's got to a point where you could see that market thriving finally? Thanks.
spk03: Sure. I have been in here. I know I'm on church for quite a bit already, but I'll take that one. So on New York with Zoom Out, as of today, we have five stores in New York. We opened up our latest store in Syracuse late last week. And, you know, look, I'll tell you that the market overall has received kind of an injection of light ever since we started seeing the state crack down these stores. And we're seeing it because we're feeling the demand on the wholesale side of the business pulling through, particularly at the retail stores that are within that, within kind of the city limits. And so we can already tell it's starting to have an impact. I mean, obviously, you know, we think they're at the early stages of this and there's a lot more room to grow. But just given the size of state, we're finally starting to see light within a market with over 20 million people that we all kind of anticipated would be there and call it, you know, five, 10 years ago. So, you know, the early stages seems like it's working, but there's more, you know, there's more work to do. We'll continue to monitor it. But definitely it's having an impact. If anything, it's just, you know, the morale of the industry within New York is a lot more positive now that, you know, it seems like, you know, it's just one less, you know, one less kind of front we have to, we
spk04: never really have to fight. Thank
spk09: you. The next question comes from Mike Regan with Excelsior equities. Please go ahead. Hi, everyone. Thanks for the question.
spk08: I guess turning to sort of the spending in Florida. Is that more just to build out the existing medical market if adult use doesn't pass in November or is it sort of an anticipation of adult use passing in November? Sort of on that, I guess any thoughts on, I guess, the yes on three campaign and additional contributions, especially now that Ken Griffin donating 12 million to fight it.
spk03: Thanks. Yeah, so Anthony here, Mike, I'll take that one as well. You know, what we're investing into Florida, irrespective of the vote in November. Right. So the vote November is just essentially more optionality on the business. You know, given the vertically integrated nature of that market, you have to invest essentially within wholesale before retail. We've done that. We're going to continue to make additional wholesale investments. We're going to continue to make additional retail investments. Now, the investments we're making today is not a bet on adult use. Now, if and when the vote goes our way, the industry's way in November, that will probably force us to revisit our capital plan to the state of Florida and revisit it then in terms of how, you know, how about initiative is looking at this moment. I mean, look, we're a number of months away. It's pretty premature at this point to really comment on it because, again, there's a lot of games being played. There's more dollars and donations are going to be coming in on both sides. The reality is that, you know, asking a couple of months, you will have a better sense for where this thing is really tracking. But here at Greensville, we're investing in the market irrespective of the vote November.
spk04: Great. Thanks a lot.
spk09: The next question comes from Scott Fortune with Roth Capital Partners. Please go ahead. Good afternoon.
spk06: Thanks for the questions. Just want to call out, we've talked a little bit about the consumer, but just want to provide a little more color on the overall consumer strength here. You guys called out, there's data indicating it's up for macro consumer spending. You guys called that out, but how is volume transactions holding up and your thoughts of where that's coming from, from that side of the thing on the consumer side? As pricing coming down, are we seeing more consumers kind of converting from the listed market or a substitution effect away from alcohol? Just kind of your overall sense on the consumer and how you guys are positioned to benefit from those trends as you get going forward here.
spk02: Thanks, Scott. Yes, Ben, I can take that. I would say overall, we see the impact. We don't think the consumers as strong as they were, but we see demand in cannabis not letting up. So transactions are not, you know, tickets are not suffering in transaction volume. You know, how to define the demand pie in cannabis remains pretty interesting and expansive and more fitting. What happens to the rules? What's going on with the illegal market? What's happening? What's at the vape store? All that sort of thing. So we continue to try to cater towards that consumer. We think the consumer is price sensitive. People care about how many dollars are in their pocket. You only have to look to like the major retailers of the country to see major signs of weakness and even today's market, etc, etc. So we don't think cannabis is totally immune, but the demand is there. The demand remains strong. Demands remain strong even when things get bad. You know, we think we'll see that with the election, with other things coming up. So, you know, headline numbers that the industry is annualizing over $30 billion. That's the first time that's happened. This thing is strong and getting stronger. So that's why I said we're confident in the future of cannabis for the American consumer. We're very confident in Green Film. We've got the buyback going. We're bullish on what we're doing here. It's a very complicated environment. And just as we conclude here, what's going on in the regulatory environment is pretty unique. We've been running the business for 10 years and we've never quite seen anything like this and nobody really knows what's going on. Nobody knows what's going on macroly, but nobody really knows what's going on in cannabis. So we're focused on how great the product is. We believe in our brands. We believe in the future. So, you know, we hope those of you that are analyzing the industry that aren't getting invested, take a real look. It's a unique opportunity. We're coming to work excited every day and look forward to talking to you again in 90 days. Thanks, Scott.
spk04: Thanks, everybody.
spk09: This concludes our question and answer session. I would like to turn the conference back over to Ben Kovala for any closing remarks.
spk02: That'll do it. Talk to you guys in 90 days.
spk09: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer